# Tipifarnib in Treating Patients With Advanced Hematologic Cancer

> **NCT00005967** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 36 (actual)

## Conditions studied

- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** tipifarnib

## Key facts

- **NCT ID:** NCT00005967
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2004-04
- **Final completion:** —
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2013-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005967, "Tipifarnib in Treating Patients With Advanced Hematologic Cancer". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00005967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*